These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 18786995)

  • 1. Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses.
    Wang BZ; Quan FS; Kang SM; Bozja J; Skountzou I; Compans RW
    J Virol; 2008 Dec; 82(23):11813-23. PubMed ID: 18786995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection.
    Wang BZ; Xu R; Quan FS; Kang SM; Wang L; Compans RW
    PLoS One; 2010 Nov; 5(11):e13972. PubMed ID: 21124769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inclusion of membrane-anchored LTB or flagellin protein in H5N1 virus-like particles enhances protective responses following intramuscular and oral immunization of mice.
    Ren Z; Zhao Y; Liu J; Ji X; Meng L; Wang T; Sun W; Zhang K; Sang X; Yu Z; Li Y; Feng N; Wang H; Yang S; Yang Z; Wang Z; Gao Y; Xia X
    Vaccine; 2018 Sep; 36(40):5990-5998. PubMed ID: 30172635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.
    Quan FS; Huang C; Compans RW; Kang SM
    J Virol; 2007 Apr; 81(7):3514-24. PubMed ID: 17251294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligand.
    Wang BZ; Gill HS; Kang SM; Wang L; Wang YC; Vassilieva EV; Compans RW
    Clin Vaccine Immunol; 2012 Aug; 19(8):1119-25. PubMed ID: 22647270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus.
    Ji X; Ren Z; Xu N; Meng L; Yu Z; Feng N; Sang X; Li S; Li Y; Wang T; Zhao Y; Wang H; Zheng X; Jin H; Li N; Yang S; Cao J; Liu W; Gao Y; Xia X
    Viruses; 2016 Apr; 8(4):115. PubMed ID: 27110810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virus-like particles containing the tetrameric ectodomain of influenza matrix protein 2 and flagellin induce heterosubtypic protection in mice.
    Wang L; Wang YC; Feng H; Ahmed T; Compans RW; Wang BZ
    Biomed Res Int; 2013; 2013():686549. PubMed ID: 23984396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virus-like particles presenting flagellin exhibit unique adjuvant effects on eliciting T helper type 1 humoral and cellular immune responses to poor immunogenic influenza virus M2e protein vaccine.
    Kim KH; Kwon YM; Lee YT; Hwang HS; Kim MC; Ko EJ; Wang BZ; Quan FS; Kang SM
    Virology; 2018 Nov; 524():172-181. PubMed ID: 30199754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The optimized fusion protein HA1-2-FliCΔD2D3 promotes mixed Th1/Th2 immune responses to influenza H7N9 with low induction of systemic proinflammatory cytokines in mice.
    Song L; Xiong D; Kang X; Jiao Y; Zhou X; Wu K; Zhou Y; Jiao X; Pan Z
    Antiviral Res; 2019 Jan; 161():10-19. PubMed ID: 30389471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge.
    Galarza JM; Latham T; Cupo A
    Viral Immunol; 2005; 18(2):365-72. PubMed ID: 16035948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine Efficacy Induced by 2009 Pandemic H1N1 Virus-Like Particles Differs from that Induced by Split Influenza Virus.
    Lee GJ; Chu KB; Inn KS; Moon EK; Quan FS
    Immunol Invest; 2020 Oct; 49(7):781-793. PubMed ID: 31774021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-delivery of GPI-anchored CCL28 and influenza HA in chimeric virus-like particles induces cross-protective immunity against H3N2 viruses.
    Mohan T; Kim J; Berman Z; Wang S; Compans RW; Wang BZ
    J Control Release; 2016 Jul; 233():208-19. PubMed ID: 27178810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flagellin-expressing virus-like particles exhibit adjuvant effects on promoting IgG isotype-switched long-lasting antibody induction and protection of influenza vaccines in CD4-deficient mice.
    Ko EJ; Lee Y; Lee YT; Jung YJ; Ngo VL; Kim MC; Kim KH; Wang BZ; Gewirtz AT; Kang SM
    Vaccine; 2019 Jun; 37(26):3426-3434. PubMed ID: 31101421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle.
    Bright RA; Carter DM; Crevar CJ; Toapanta FR; Steckbeck JD; Cole KS; Kumar NM; Pushko P; Smith G; Tumpey TM; Ross TM
    PLoS One; 2008 Jan; 3(1):e1501. PubMed ID: 18231588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Correlates of Protection Induced by Virus-Like Particles Containing 2009 H1N1 Pandemic Influenza HA, NA or M1 Proteins.
    Moon EK; Kang HJ; Chu KB; Lee SH; Lee DH; Soh Y; Quan FS
    Immunol Invest; 2019 May; 48(4):355-366. PubMed ID: 30430891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
    Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
    Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.